RJA
CNMD icon

Raymond James & Associates’s CONMED CNMD Stock Holding History

Raymond James & Associates’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$10.2M Buy
141,907
+58,663
+70% +$4.14M 0.01% 1224
2024
Q2 		$5.77M Sell
83,244
-1,391
-2% -$101K ﹤0.01% 1480
2024
Q1 		$6.78M Buy
84,635
+4,231
+5% +$377K ﹤0.01% 1380
2023
Q4 		$8.8M Sell
80,404
-2,555
-3% -$264K 0.01% 1183
2023
Q3 		$8.37M Buy
82,959
+2,131
+3% +$245K 0.01% 1152
2023
Q2 		$11M Sell
80,828
-22,165
-22% -$2.71M 0.01% 995
2023
Q1 		$10.7M Buy
102,993
+10,259
+11% +$992K 0.01% 990
2022
Q4 		$8.22M Sell
92,734
-3,383
-4% -$281K 0.01% 1109
2022
Q3 		$7.71M Sell
96,117
-8,136
-8% -$767K 0.01% 1105
2022
Q2 		$9.98M Sell
104,253
-930
-0.9% -$112K 0.01% 980
2022
Q1 		$15.6M Buy
105,183
+2,309
+2% +$322K 0.01% 830
2021
Q4 		$14.6M Sell
102,874
-695
-0.7% -$98.4K 0.01% 905
2021
Q3 		$13.6M Buy
103,569
+11,532
+13% +$1.51M 0.01% 898
2021
Q2 		$12.6M Buy
92,037
+16
+0% +$2.19K 0.01% 947
2021
Q1 		$12M Buy
92,021
+4,612
+5% +$555K 0.01% 923
2020
Q4 		$9.79M Buy
87,409
+2,307
+3% +$218K 0.01% 963
2020
Q3 		$6.7M Sell
85,102
-2,182
-2% -$178K 0.01% 1062
2020
Q2 		$6.28M Buy
87,284
+12,032
+16% +$837K 0.01% 1061
2020
Q1 		$4.31M Buy
75,252
+28,177
+60% +$2.6M 0.01% 1124
2019
Q4 		$5.26M Buy
47,075
+885
+2% +$94.3K 0.01% 1207
2019
Q3 		$4.44M Buy
46,190
+4,914
+12% +$461K 0.01% 1301
2019
Q2 		$3.53M Buy
41,276
+13,107
+47% +$1.08M 0.01% 1443
2019
Q1 		$2.34M Buy
+28,169
New +$2.05M ﹤0.01% 1662

Other funds holding CNMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Raymond James & Associates's CNMD Position: Q3 2024 in Review

Raymond James & Associates increased its CONMED (CNMD) stake by 70% in Q3 2024, buying an estimated $4.14M and bringing the position to 141,907 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #1224.

Raymond James & Associates first reported a position in CNMD in Q1 2019 and has held it in 23 quarters since. The position peaked at $15.6M in Q1 2022. 290 funds tracked by Wall St. Rank hold CNMD as of Q3 2024.

  • Raymond James & Associates held 141,907 shares of CONMED worth $10.2M as of Q3 2024.
  • Raymond James & Associates bought 58,663 CONMED shares in Q3 2024, an estimated $4.14M.
  • CONMED made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1224 holding.
  • Raymond James & Associates first reported a position in CONMED in Q1 2019 and has held it in 23 quarters since.
  • Raymond James & Associates's CONMED position peaked at $15.6M in Q1 2022.
  • 290 funds tracked by Wall St. Rank held CONMED as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.